HIV News and Research

RSS

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

4 Apr 2005

UK sex clinics swamped

A study, by sexual health charity the Terrence Higgins Trust, reveals the true scale of Britain's sexual health crisis and says that two-thirds of clinics are turning away patients because they cannot cope with demand for treatment.

4 Apr 2005

New chemicals to inhibit HIV infection

In corporation with peers from the Mount Sinai School of Medicine, New York University, researchers from the University of Science and Technology of China (USTC), a CAS affiliate, have come up with new chemical inhibitors against HIV reproduction, marking a significant progress in the development of anti-AIDS drugs based on natural host resistance.

4 Apr 2005

Moderate aerobic exercise improves cardiovascular and nervous system function in HIV+ subjects

Researchers from Teachers College, Columbia University, and Coler Goldwater Specialty Hospital and Nursing Facility report that moderate aerobic exercise for 10 weeks, three times a week for 45 minutes each session significantly improved function of the nervous system and circulation in those with HIV disease.

3 Apr 2005

First UK cases of previously rare disease reported in gay men

A previously rare disease has been reported for the first time in the UK, Lymphograunuloma venereum (LGV) is a genital/anogenital bacterial infection caused by a particularly invasive strain of Chlamydia trachomatis.

3 Apr 2005

New drug approved for treating endometriosis

Drug manufacturer Pfizer announced today that the U.S. Food and Drug Administration (FDA) has given approval for the release of depo-subQ provera 104 to be prescribed for the management of pain associated with endometriosis, a gynecological condition that affects one in ten women of reproductive age.

30 Mar 2005

Drug-resistant HIV identified in New York

Health officials in New York say they have identified several patients who may have been infected with a rare strain of highly drug-resistant HIV, but whether the cases are related is uncertain at this stage.

30 Mar 2005

Primary health care providers should incorporate HIV testing into routine patient care for all sexually active individuals

Primary health care providers should incorporate human immunodeficiency virus (HIV) testing into routine patient care for all sexually active individuals, regardless of risk factors, say a group of physician/researchers at Emory University School of Medicine, Brown Medical School, and the Johns Hopkins School of Medicine.

30 Mar 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

HIV patients who delay seeking care are much sicker when they begin care

Patients recently diagnosed with human immunodeficiency virus (HIV) are significantly more likely to seek medical treatment if they are followed even briefly by a case manager, according to findings of the national Antiretroviral Treatment Access Study (ARTAS).

30 Mar 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Surprising discovery about natural immunity to pneumococcus

Since 2000, U.S. infants have been routinely immunized against pneumococcal (Streptococcus pneumoniae) infection. Now, Boston researchers have made a surprising discovery about natural immunity to pneumococcus.

29 Mar 2005

AIDS virus initially more destructive than first thought

The AIDS virus destroys more than half of the immune cells that might recognize and help fight it, within days of infection according to US researchers, and this revelation might necessitate a re-evaluation of how the deadly infection should be tackled.

28 Mar 2005

Vaccine prevents deadly pneumonia in African children

Global health leaders today presented new research showing that vaccinating infants against Streptococcus pneumoniae -- a bacterium that causes deadly pneumonia, meningitis and sepsis -- could substantially reduce death and serious illness among children in the developing world. If used widely, a pneumococcal conjugate vaccine could prevent hundreds of thousands of child deaths each year.

28 Mar 2005

Research tool for turning off genes may eventually have therapeutic application

A research team based at Massachusetts General Hospital (MGH) has identified 80 new genes essential to the process of RNA interference (RNAi), a powerful new research tool for inactivating genes in plants or animals.

28 Mar 2005

New therapy for treating cat allergies looks promising

Andrew Saxon, M.D., and a team of researchers at University of California, Los Angeles (UCLA) have found that a molecule designed to block cat allergies can prevent allergic reactions in laboratory mice and was also successful when tested on human cells in a test tube.

28 Mar 2005

Rejected asylum seekers and illegal immigrants should get HIV treatment free on the National Health Service

MPs on the Commons health select committee say, in a strongly worded report, that rejected asylum seekers and illegal immigrants should get HIV treatment free on the National Health Service (NHS) like everybody else, to avoid the risk of a further spread of Aids; they say the government's withdrawal of free treatment from these groups as a measure against "health tourism" was ill-advised.

23 Mar 2005

India passes the drug Patent Bill

India's parliament passed a new law Wednesday, the Patent (Amendment) Bill, prohibiting the copying of patented drugs, despite strong criticism that the legislation would prohibit the manufacture of low-cost generic drugs.

23 Mar 2005

Promising results reported for HIV patients suffering from facial wasting

Physicians from leading plastic surgery and dermatology practices report positive results from HIV patients participating in a clinical trial of Radiesse synthetic injectable implant on facial wasting. The trial is intended to demonstrate the safety and effectiveness of this widely used tissue augmentation therapy as a treatment for the facial changes that socially stigmatize many HIV-infected patients.

23 Mar 2005

Ranbaxy files additional Anti-Retroviral (ARV) agents with the World Health Organization

Ranbaxy Laboratories Limited (RLL) announced today that the Company has made two additional filings of its Anti-Retroviral (ARV) agents with the World Health Organization (WHO) for its approval, taking the total number of Ranbaxy ARV filings submitted with the WHO to five.

23 Mar 2005